Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 22,226 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: control 2 Clear all

Conditions: Steatotic Liver Disease of Mixed Origin (MetALD)
Interventions: Brief motivational interviewing with personalized feedback, Brief motivational interviewing with standard health information; Behavioral
Lead sponsor: Brown University; Other
Eligibility: 21 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Bicep Tendinitis, Biceps; Tenosynovitis, Bicipital Tendinitis, Left Shoulder, Bicipital Tendinitis, Right Shoulder, Bicipital Tendinitis, Unspecified Shoulder, Biceps Tendon Disorder
Interventions: Dry Needling, Heavy Slow Load Exercise, Rotator cuff and scapular stabilization exercise program, Soft tissue mobilization; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Aurora, Colorado • Boulder, Colorado

Conditions: Periprosthetic Joint Infection (PJI)
Interventions: Ultrasound-triggered microbubble destruction with antibiotics; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania • Dallas, Texas

Conditions: Hypertriglyceridemia
Interventions: Epanova, Olive Oil; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Los Angeles, California • St. Petersburg, Florida • Addison, Illinois + 11 more

Conditions: Oral Mucositis
Interventions: AG013, Placebo; Biological · Other
Lead sponsor: Oragenics, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 27
States / cities: Farmington, Connecticut • Newark, Delaware • Orlando, Florida + 24 more

Conditions: Healthy Subjects
Interventions: TI Inhalation Powder; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy
Interventions: Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp), MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.], MVA-BN-Filo 5*10^7 Inf. U., Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 525 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Interventions: SAR443820, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: COVID-19, Coronavirus, SARS-CoV2 Infection
Interventions: Rayaldee, Placebo; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: San Francisco, California • Miami, Florida • Evanston, Illinois + 6 more

Conditions: Lymphedema
Interventions: Aquatic Exercise arm; Behavioral
Lead sponsor: Baylor Research Institute; Other
Eligibility: 21 Years to 90 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: Placebo, RSV preF Protein 50 mcg, RSV preF Protein 150 mcg, Ad26.RSV.preF 1*10^11 vp, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg, Selected Regimen; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years and older
Enrollment: 669 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Lung; Node
Interventions: RAB via the Monarch platform, RAB via the ION platform; Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy
Interventions: Dasatinib, Quercetin, Fisetin; Drug
Lead sponsor: Sundeep Khosla, M.D.; Other
Eligibility: 60 Years and older · Female only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Burns
Interventions: cNP8, Placebo; Drug · Other
Lead sponsor: Neomatrix Therapeutics, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Elopement, Autism Spectrum Disorder
Interventions: Universal Safety Measures Module (All participants), Proximity Training Module (Bolting Prevention Participants), Check-In Training Module (Wandering Prevention Participants); Behavioral
Lead sponsor: Emory University; Other
Eligibility: 4 Years to 12 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Long COVID, Long Covid19
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 5,205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Cystic Fibrosis
Interventions: Vanzacaftor, Vanzacaftor Placebo, Moxifloxacin, Moxifloxacin Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Autism, Severe Behavior Disorder
Interventions: placebo, glutathione, glutathione, vit C and NAC; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 5 Years to 16 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions: shark cartilage extract AE-941, placebo, cisplatin, vinorelbine tartrate, carboplatin, paclitaxel, radiation therapy; Drug · Other · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glaucoma
Interventions: Computer Tablet, Continuing Education Course, Continuing education; Other
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 721 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: Birmingham, Alabama • Durham, North Carolina

Conditions: Bipolar I Disorder, Bipolar II Disorder
Interventions: Icalcaprant, Placebo for Icalcaprant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 33
States / cities: Huntsville, Alabama • Chandler, Arizona • Tucson, Arizona + 29 more

Conditions: Dry Eye Syndrome
Interventions: 0.3% BOL-303242-X ophthalmic suspension, 2% BOL-303242-X ophthalmic suspension, Placebo Comparator: Vehicle, 1% BOL-303242-X ophthalmic suspension, 2% BOL-303242-X ophthalmic suspension AM, 2% BOL-303242-X ophthalmic suspension PM; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Chemotherapy-induced Neutropenia
Interventions: EC-18, Placebo; Drug
Lead sponsor: Enzychem Lifesciences Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Pulmonary Embolism
Interventions: Adient absorbable filter + best practice VTE prophylaxis, best practice VTE prophylaxis; Device
Lead sponsor: Adient Medical; Industry
Eligibility: 18 Years and older
Enrollment: 854 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Indianapolis, Indiana

Search by objective public record fields.

Team Science (The Liver Health Study)

Dry Needling and Exercise Versus Traditional Physical Therapy for Biceps Tendinitis

Periprosthetic Joint Infection Bubble Study

Epanova® for Lowering Very High Triglycerides II (EVOLVE II)

Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day

A Trial to Determine How Long Insulin and FDKP (the Molecule That Forms Technosphere Particles) Stays in the Lungs of Healthy Individuals After Inhalation of Technosphere® Insulin (TI) Powder Using Bronchoalveolar Lavage (BAL)

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants

Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

Aquatic Exercise Study for Breast Cancer Patients With Lymphedema

A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

Robotic Systems Evaluation for Peripheral Pulmonary Lesions (RISE Trial)

Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans

Phase 1 Healthy Volunteer Burn Therapy Study

A Study of the Elopement Prevention and Safety Training Program

Understanding the Long-term Impact of COVID-19 in Adults

An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems

Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery

Partnership for Glaucoma

A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome

A Safety and PK Study of EC-18 in Healthy Subjects

US Pivotal Clinical Study of the Adient Absorbable Filter for the Prevention of Pulmonary Embolism